EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A circular RNA overcomes acquired resistance to BET inhibitors by antagonizing IGF2BP2-mediated c-MYC translation in TNBC

Jiawei Guo iD, Ke Li iD, Yue Ming, Yitong Pan, Shuangyan Tan iD, Hulin Ma, Shuang Chen iD, Yingying Duan iD, Yong Peng iD

Proceedings of the National Academy of Sciences · 2025

DOI: 10.1073/pnas.2504320122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Jiawei Guo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Molecular Oncology, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, …. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, RNA, Circular, RNA-Binding Proteins, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Foundation of Sichuan Province, China, the Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bromodomain-and-extraterminal-domain (BET) proteins are promising therapeutic targets for refractory solid tumors, including triple-negative breast cancer (TNBC). However, acquired resistance to BET inhibitors (BETi) remains a significant clinical challenge. Elucidation of the underlying mechanisms of BETi resistance is therefore of critical importance. In this study, we identified the RNA-binding protein IGF2BP2 as a key driver of acquired BETi resistance in TNBC, primarily through its role in enhancing the translation of c-MYC mRNA. Given that IGF2BP2 is not an ideal target for small-molecular drugs, we performed RNA immunoprecipitation sequencing (RIP-Seq) and found circRNA-BISC as a potent IGF2BP2 repressor. BISC effectively inhibited both c-MYC translation and BETi resistance. Notably, BISC contains a “CAC-linker-XGGX” motif that specifically binds IGF2BP2 rather than to IGF2BP1 and IGF2BP3. The efficacy and selectivity of BISC in targeting IGF2BP2 prompted further exploration of BISC-based RNA therapeutics for TNBC. In vitro transcribed and circularized BISC, when combined with the BETi OTX-015, demonstrated impressive tumor regression in BETi-resistant TNBC models without detectable toxicity. These findings establish BISC as a potent IGF2BP2 repressor and highlight the feasibility of circRNA-based therapeutic strategies to overcome BETi resistance in TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsRNA, CircularRNA-Binding ProteinsDrug Resistance, NeoplasmProto-Oncogene Proteins c-mycHumansCell Line, TumorAnimalsMiceFemaleProtein BiosynthesisGene Expression Regulation, NeoplasticXenograft Model Antitumor AssaysBromodomain Containing ProteinsProteins

Stichwörter der Autor:innen

BET inhibitorsIGF2BP2acquired drug resistancec-MYC translationcircular RNA

Substanzen

RNA, CircularRNA-Binding ProteinsProto-Oncogene Proteins c-mycIGF2BP2 protein, humanMYC protein, humanbromodomain and extra-terminal domain protein, humanBromodomain Containing ProteinsProteins

Autor:innen und Institutionen

  • Center for Molecular Oncology, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, State Key Laboratory of Respiratory Health and Multimorbidity, West Ch…
  • Tianfu Jincheng Laboratory, Chengdu 610212, China.

ORCID-Profile: Jiawei Guo, Ke Li, Shuangyan Tan, Shuang Chen, Yingying Duan, Yong Peng

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Foundation of Sichuan Province, China
  • the Fundamental Research Funds for the Central Universities
  • 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University

Zitieren

APA

Guo, J., Li, K., Ming, Y., Pan, Y., Tan, S., Ma, H., Chen, S., Duan, Y., & Peng, Y. (2025). A circular RNA overcomes acquired resistance to BET inhibitors by antagonizing IGF2BP2-mediated c-MYC translation in TNBC. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2504320122

Vancouver

Guo J, Li K, Ming Y, Pan Y, Tan S, Ma H, et al. A circular RNA overcomes acquired resistance to BET inhibitors by antagonizing IGF2BP2-mediated c-MYC translation in TNBC. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2504320122

BibTeX
@article{Guo2025,
  author = {Guo, Jiawei and Li, Ke and Ming, Yue and Pan, Yitong and Tan, Shuangyan and Ma, Hulin and Chen, Shuang and Duan, Yingying and Peng, Yong},
  title = {A circular RNA overcomes acquired resistance to BET inhibitors by antagonizing IGF2BP2-mediated c-MYC translation in TNBC},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  doi = {10.1073/pnas.2504320122}
}
Kostenlos starten →